Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban and ASA in Coronary Artery Disease
NCT05210725Phase 4Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2022
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in coronary artery disease (CAD), sponsored by Radboud University Medical Center. Primary endpoint: Whole blood immune responsiveness at 12 weeks. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05210725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05210725.